Margin Pressure, Sluggish Private Label Business and Rising Operating Costs Trigger Sharp Sell-Off; Analysts Continue to See Long-Term Value

Shares of MedPlus Health Services Ltd. came under intense selling pressure on Wednesday after the pharmacy retail chain reported a disappointing set of first-quarter FY27 results. The stock tumbled as much as 18% intraday, making it one of the biggest losers on Dalal Street, as investors reacted to a sharp decline in profitability despite robust revenue growth.

While MedPlus delivered healthy double-digit sales growth during the June quarter, weaker gross margins, rising employee expenses, and slower growth in its high-margin private label portfolio weighed heavily on earnings. The disappointing quarterly performance overshadowed the company's continued expansion across India's fast-growing organised pharmacy market.

Despite the near-term weakness, brokerage firm Nomura maintained its 'Buy' rating on the stock, suggesting that the long-term growth story remains intact even as investors await signs of margin recovery.

MedPlus Shares Witness Heavy Selling

The stock opened sharply lower following the earnings announcement and continued to decline during the trading session as investors reacted to weaker-than-expected profitability.

Stock Performance Snapshot

The stock has significantly underperformed the broader market across multiple timeframes, reflecting investor concerns over earnings quality and margin sustainability.

Q1FY27 Results: Revenue Grows, Profit Declines

MedPlus reported healthy top-line growth during the quarter but failed to translate higher sales into improved profitability.

Q1FY27 Financial Highlights

The company's revenue growth remained strong, supported by continued expansion in its pharmacy business and increasing consumer demand for healthcare products. However, profit margins came under pressure due to rising operating costs and lower contribution from higher-margin products.

Private Label Business Emerges as Key Concern

One of the biggest disappointments during the quarter was the slowdown in MedPlus' private label business.

Private label products are strategically important because they typically generate higher gross margins than branded pharmaceutical products.

However, during Q1FY27:

• Private label sales increased only 2% year-on-year.

• Gross profit growth slowed considerably.

• Margin contribution weakened.

The sluggish performance of this segment became one of the primary reasons behind the decline in overall profitability.

Gross Margins Under Pressure

Despite recording over 21% revenue growth, MedPlus reported one of its weakest gross profit performances in recent years.

Key highlights include:

• Gross profit growth of approximately 14%.

• Gross margin contraction of 163 basis points year-on-year.

• Slowest gross profit growth in nearly four years.

According to analysts, increased contribution from franchisee sales also weighed on consolidated margins during the quarter.

Rising Employee Costs Impact Profitability

Operating expenses increased sharply during the quarter, further pressuring earnings.

Major cost pressures included:

• Pharmacy employee salaries rising nearly 30% year-on-year.

• Higher store operating expenses.

• Increased administrative overheads.

While the company continues expanding its retail footprint, rising costs have temporarily offset the benefits of higher sales.

Operating Performance Misses Expectations

The combination of slower margin growth and higher operating costs significantly impacted earnings before interest, tax, depreciation, and amortisation (EBITDA).

Analysts estimate:

• Operating EBITDA declined approximately 11% year-on-year.

• EBITDA was nearly 29% below market expectations.

The sharp earnings miss triggered a negative reaction from investors despite the healthy revenue performance.

Nomura Maintains Positive Long-Term View

Despite the disappointing quarterly numbers, global brokerage Nomura retained its positive recommendation on MedPlus.

Brokerage Recommendation

According to Nomura:

• Revenue growth remains healthy.

• Organised pharmacy market continues to expand.

• Store network growth remains encouraging.

• Long-term healthcare demand remains favourable.

However, the brokerage acknowledged that weak private label growth and higher operating costs negatively impacted quarterly earnings.

India's Organised Pharmacy Market Continues to Expand

MedPlus remains one of India's largest organised pharmacy chains.

The company currently operates across:

• 13 States

• 1 Union Territory

Major markets include:

• Hyderabad

• Bengaluru

• Chennai

• Mumbai

• Pune

• Kolkata

• Nagpur

• Visakhapatnam

Besides prescription medicines, MedPlus also offers diagnostics, healthcare products, wellness items, and private label brands.

Its wide geographic presence continues to provide long-term growth opportunities as India's healthcare sector expands.

Industry Outlook Remains Positive

India's organised pharmacy sector continues to benefit from strong structural growth drivers.

Key Growth Drivers

• Rising healthcare expenditure.

• Growing ageing population.

• Increasing prevalence of chronic diseases.

• Expansion of organised retail.

• Rising health insurance penetration.

• Higher demand for diagnostics.

• Growth in preventive healthcare.

However, companies also face challenges from:

• Margin pressure.

• Intense competition.

• Rising employee costs.

• Expansion-related investments.

• Online pharmacy competition.

Managing profitability while maintaining growth remains the industry's biggest challenge.

Should Investors Consider Buying the Dip?

The sharp correction has significantly reduced MedPlus' market valuation.

Factors Supporting Long-Term Investment

• Strong revenue growth.

• Large and expanding pharmacy network.

• Long-term healthcare consumption trend.

• Organised retail penetration.

• Positive brokerage outlook.

Risks to Watch

• Weak private label growth.

• Margin compression.

• Higher salary expenses.

• Slower earnings growth.

• Competitive intensity.

Long-term investors may consider monitoring upcoming quarterly results to assess whether management can successfully restore margins before taking fresh positions.

Smart Investment Analysis

MedPlus' Q1FY27 results illustrate that revenue growth alone is not sufficient to drive shareholder returns if profitability remains under pressure. While the company's nationwide retail network and favourable industry dynamics continue to support its long-term growth story, the recent slowdown in its high-margin private label business and rising operating costs have raised concerns about earnings quality. Going forward, investors will closely watch management's efforts to improve gross margins, enhance operating efficiency, and accelerate private label sales, which will be crucial for rebuilding market confidence.

Key Takeaways

• MedPlus shares plunged nearly 18% after reporting weaker-than-expected Q1FY27 earnings.

• Net profit declined 21.7% to ₹33.2 crore, despite 21.8% growth in revenue.

• Weak private label sales, margin contraction, and higher employee expenses impacted profitability.

• Gross margins declined by 163 basis points, while operating EBITDA missed market expectations.

• Nomura maintained its 'Buy' rating with a target price of ₹1,190, citing favourable long-term growth prospects.

• Investors will closely monitor margin recovery and the performance of the company's higher-margin private label business over the coming quarters.